000280229 001__ 280229
000280229 005__ 20250822101711.0
000280229 0247_ $$2doi$$a10.1055/a-2566-1487
000280229 0247_ $$2pmid$$apmid:40233814
000280229 0247_ $$2pmc$$apmc:PMC12328034
000280229 0247_ $$2ISSN$$a0029-5566
000280229 0247_ $$2ISSN$$a2567-6407
000280229 037__ $$aDZNE-2025-00907
000280229 041__ $$aEnglish
000280229 082__ $$a610
000280229 1001_ $$00000-0002-0945-0724$$aBuchert, Ralph$$b0
000280229 245__ $$aNeurobildgebung mit SPECT und PET in Deutschland: Ergebnisse der 1. Umfrage zur nuklearmedizinischen Neurobildgebung in Deutschland 2023.
000280229 260__ $$aStuttgart$$bThieme$$c2025
000280229 3367_ $$2DRIVER$$aarticle
000280229 3367_ $$2DataCite$$aOutput Types/Journal article
000280229 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1754898185_31915
000280229 3367_ $$2BibTeX$$aARTICLE
000280229 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000280229 3367_ $$00$$2EndNote$$aJournal Article
000280229 520__ $$aThe advent of disease-modifying therapies for neurodegenerative diseases may result in a growing demand for nuclear neuroimaging procedures presenting opportunities but also challenges to the nuclear medicine community. Whether capacity and expertise in Germany are sufficient to meet an increasing demand for nuclear neuroimaging is under discussion. Against this background, the Neuroimaging Working Group of the German Society of Nuclear Medicine initiated the first survey on the status of nuclear neuroimaging in Germany in 2023. 82 institutions participated in the survey: 33 practices, 15 community hospitals, 34 university hospitals. Primary findings were the following. In practices, brain scans are less frequently performed than in hospitals and are often limited to dopamine transporter SPECT. Brain PET is mainly performed in hospitals, and in community hospitals it is often restricted to FDG PET. Nevertheless, availability of amyloid PET with well-certified quality can be taken for granted. Thus, access to amyloid PET will not be a major bottleneck for new treatments of Alzheimer's disease. Adequate reimbursement and clear anchoring in clinical guidelines have the greatest potential to advance nuclear neuroimaging in Germany. Clinical dopamine transporter SPECT is largely in agreement with procedure guidelines. An area for improvement is the limited availability of MR images to avoid misinterpretation of structural/vascular lesions as nigrostriatal degeneration. The survey provides the first systematic assessment of the status of nuclear neuroimaging in Germany. It underscores the capacity of the German nuclear medicine community to meet an increasing demand for neuroimaging procedures, its adherence to procedure guidelines and identifies topics for improvement.
000280229 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000280229 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000280229 650_2 $$2MeSH$$aGermany
000280229 650_2 $$2MeSH$$aHumans
000280229 650_2 $$2MeSH$$aTomography, Emission-Computed, Single-Photon: statistics & numerical data
000280229 650_2 $$2MeSH$$aPositron-Emission Tomography: statistics & numerical data
000280229 650_2 $$2MeSH$$aNeuroimaging: statistics & numerical data
000280229 650_2 $$2MeSH$$aNeuroimaging: methods
000280229 650_2 $$2MeSH$$aSurveys and Questionnaires
000280229 650_2 $$2MeSH$$aBrain: diagnostic imaging
000280229 7001_ $$0P:(DE-2719)2811239$$aDrzezga, Alexander$$b1$$eFirst author$$udzne
000280229 7001_ $$aSchreckenberger, Mathias$$b2
000280229 7001_ $$aLangen, Karl Josef$$b3
000280229 7001_ $$aMeyer, Philipp T$$b4
000280229 7001_ $$aMedicine, Working Group Nuclear Neuroimaging of the German Society of Nuclear$$b5$$eCollaboration Author
000280229 773__ $$0PERI:(DE-600)2030804-8$$a10.1055/a-2566-1487$$gVol. 64, no. 4, p. 250 - 261$$n4$$p250 - 261$$tNuklearmedizin$$v64$$x0029-5566$$y2025
000280229 8564_ $$uhttps://pub.dzne.de/record/280229/files/DZNE-2025-00907.pdf$$yOpenAccess
000280229 8564_ $$uhttps://pub.dzne.de/record/280229/files/DZNE-2025-00907%20SUP.pdf
000280229 8564_ $$uhttps://pub.dzne.de/record/280229/files/DZNE-2025-00907%20SUP.pdf?subformat=pdfa$$xpdfa
000280229 8564_ $$uhttps://pub.dzne.de/record/280229/files/DZNE-2025-00907.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000280229 909CO $$ooai:pub.dzne.de:280229$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000280229 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811239$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000280229 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000280229 9141_ $$y2025
000280229 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-02
000280229 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-02
000280229 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000280229 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-02
000280229 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000280229 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-02
000280229 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-02
000280229 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-02
000280229 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-02
000280229 9201_ $$0I:(DE-2719)1011202$$kAG Boecker$$lPositron Emissions Tomography (PET)$$x0
000280229 980__ $$ajournal
000280229 980__ $$aVDB
000280229 980__ $$aUNRESTRICTED
000280229 980__ $$aI:(DE-2719)1011202
000280229 9801_ $$aFullTexts